Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies

被引:7
作者
Xavier, Ana C. [1 ]
Costa, Luciano J. [2 ]
机构
[1] Univ Alabama Birmingham, Dept Pediat, Div Hematol & Oncol, Birmingham, AL USA
[2] Univ Alabama Birmingham, Dept Med, Div Hematol & Oncol, Birmingham, AL 35294 USA
关键词
Hodgkin lymphoma; second malignancy; radiotherapy; SEER program; outcome research; CHEMOTHERAPY; RADIOTHERAPY; RISK; MORTALITY; LEUKEMIA; DISEASE;
D O I
10.3109/10428194.2014.983097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Omission of radiation therapy (RT) in adolescents and young adults (AYA) with early classical Hodgkin lymphoma (cHL) may affect survival and risk of second malignancies (SMN). Using the Surveillance, Epidemiology and End Results database we found reduction in RT use from 60.8% among 2614 cases from 1995 to 2002 to 52.9% among 2542 cases from 2003 to 2010, p < 0.001. Survival at 5 years with and without RT was 95.1% vs. 93.3%, p = 0.013 for 1995-2002 and 97.7% vs. 96.4%, p = 0.021 for 2003-2010. Omission of RT was affected by 2003-2010 era, race-ethnicity, income and education and independently increased the risk of death (hazard ratio 1.34, p = 0.011). The cumulative risk of SMN at 150 months was 3.3% vs. 3.0% (p = 0.87) while the risk of death without SMN (competing risk) was 5.7% vs. 8.8% for RT and no-RT patients, respectively (p = 0.0009). Omission of RT for early cHL in AYA may increase mortality without reduction in SMN.
引用
收藏
页码:2339 / 2343
页数:5
相关论文
共 23 条
  • [1] Long-term cause-specific mortality of patients treated for Hodgkin's disease
    Aleman, BMP
    van den Belt-Dusebout, AW
    Klokman, WJ
    van't Veer, MB
    Bartelink, H
    van Leeuwen, FE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3431 - 3439
  • [2] [Anonymous], 2012, Blood, DOI [10.1182/blood.V120.21.547.547, DOI 10.1182/BLOOD.V120.21.547.547]
  • [3] [Anonymous], SEER CANC STAT REV 1
  • [4] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group
    Bhatia, S
    Yasui, Y
    Robison, LL
    Birch, JM
    Bogue, MK
    Diller, L
    DeLaat, C
    Fossati-Bellani, F
    Morgan, E
    Oberlin, O
    Reaman, G
    Ruymann, FB
    Tersak, J
    Meadows, AT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4386 - 4394
  • [5] Brusamolino E, 1998, HAEMATOLOGICA, V83, P812
  • [6] Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study
    Castellino, Sharon M.
    Geiger, Ann M.
    Mertens, Ann C.
    Leisenring, Wendy M.
    Tooze, Janet A.
    Goodman, Pam
    Stovall, Marilyn
    Robison, Leslie L.
    Hudson, Melissa M.
    [J]. BLOOD, 2011, 117 (06) : 1806 - 1816
  • [7] SOCIOECONOMIC-STATUS AND CANCER SURVIVAL
    CELLA, DF
    ORAV, EJ
    KORNBLITH, AB
    HOLLAND, JC
    SILBERFARB, PM
    LEE, KW
    COMIS, RL
    PERRY, M
    COOPER, R
    MAURER, LH
    HOTH, DF
    PERLOFF, M
    BLOOMFIELD, CD
    MCINTYRE, OR
    LEONE, L
    LESNICK, G
    NISSEN, N
    GLICKSMAN, A
    HENDERSON, E
    BARCOS, M
    CRICHLOW, R
    FAULKNER, CS
    EATON, W
    NORTH, W
    SCHEIN, PS
    CHU, F
    KING, G
    CHAHINIAN, AP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) : 1500 - 1509
  • [8] Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95
    Doerffel, Wolfgang
    Ruehl, Ursula
    Lueders, Heike
    Claviez, Alexander
    Albrecht, Marion
    Boekkerink, Jos
    Holte, Harald
    Karlen, Jonas
    Mann, Georg
    Marciniak, Heinz
    Niggli, Felix
    Schmiegelow, Kjeld
    Schwarze, Ernst-Wilhelm
    Poetter, Richard
    Wickmann, Lutz
    Schellong, Guenther
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) : 1562 - 1568
  • [9] Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma:: Final results of the GHSG HD7 trial
    Engert, Andreas
    Franklin, Jeremy
    Eich, Hans Theodor
    Brillant, Corinne
    Sehlen, Susanne
    Cartoni, Claudio
    Herrmann, Richard
    Pfreundschuh, Michael
    Sieber, Markus
    Tesch, Hans
    Franke, Astrid
    Koch, Peter
    de Wit, Maike
    Paulus, Ursula
    Hasenclever, Dirk
    Loeffler, Markus
    Mueller, Rolf-Peter
    Mueller-Hermelink, Hans Konrad
    Duehmke, Eckhart
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3495 - 3502
  • [10] Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
    Engert, Andreas
    Pluetschow, Annette
    Eich, Hans Theodor
    Lohri, Andreas
    Doerken, Bernd
    Borchmann, Peter
    Berger, Bernhard
    Greil, Richard
    Willborn, Kay C.
    Wilhelm, Martin
    Debus, Juergen
    Eble, Michael J.
    Soekler, Martin
    Ho, Antony
    Rank, Andreas
    Ganser, Arnold
    Truemper, Lorenz
    Bokemeyer, Carsten
    Kirchner, Hartmut
    Schubert, Joerg
    Kral, Zdenek
    Fuchs, Michael
    Mueller-Hermelink, Hans-Konrad
    Mueller, Rolf-Peter
    Diehl, Volker
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) : 640 - 652